Three quarterly reports exceed expectations, many pharmaceutical machinery companies are optimistic about institutions

A few days ago, listed pharmaceutical equipment companies have successively released three quarterly reports.
On the whole, with the successive delivery of orders from major companies, new products have gradually shown results, and industry performance has maintained a growth trend
.
In response to the three quarterly reports of Chutian, Tofflon and other listed pharmaceutical machinery companies exceeding expectations, a number of institutions issued "optimistic" research reports and maintained a "buy" rating
.
Three quarterly reports exceeded expectations.
In the first three quarters of this year, many pharmaceutical machinery companies exceeded expectations in their third quarter reports, doubling their net profit growth
.
For example, Tofflon issued a third-quarter results announcement on the evening of October 27, stating that the net profit attributable to shareholders of listed companies in the first three quarters was about 558 million yuan, a year-on-year increase of nearly double, an increase of 93.
69%
.
Among them, in the third quarter of 2021, the company's net profit attributable to the parent was 218 million yuan, a year-on-year increase of 87.
69%
.
It is reported that the growth of Tofflon's performance is mainly due to the gradual results of the company's new products and new markets in various business segments over the years
.
Chutian Technology achieved a net profit of 401 million yuan attributable to shareholders of listed companies in the first three quarters, a year-on-year increase of 723.
53%, and its net profit reached twice the net profit for the full year of 2020
.
Among them, in the third quarter and single quarter, the company achieved a net profit of 165 million yuan attributable to shareholders of listed companies, an increase of 413.
91% year-on-year, maintaining high growth
.
During the reporting period, the company's new orders and orders in hand increased significantly, which drove the growth of operating income and operating costs
.
In addition, Chutian Technology’s contract liabilities amounted to 2.
534 billion yuan, an increase of 134.
22% from the beginning of the year
.
Relevant people believe that Chutian Technology has sufficient orders in hand, and the fourth quarter and subsequent quarters are expected to maintain high growth
.
Institutions are optimistic about the future of these companies.
In response to the recent three quarterly reports of listed pharmaceutical companies, Guosheng Securities, Guohai Securities, Essence Securities, Southwest Securities and other institutions issued "optimistic" research reports and maintained the "buy" rating.

.
For example, since October 12, three securities institutions including Guosheng Securities, Guohai Securities, Essence Securities, Guosheng Securities, and Essence Securities have successively issued "Three quarterly reports exceed expectations, industry + company resonance drives continued high growth in performance", " Comment on the Q3 performance forecast for 2021: Order structure continues to improve, the leader of the entire industry chain is beginning to show up, the third quarterly report is in line with expectations, the domestic biopharmaceutical equipment leader continues to grow at a high rate, and the third quarterly report exceeds expectations, taking the golden period of biopharmaceuticals , Domestic leaders accelerate breakthroughs at home and abroad", "Three quarterly report results in line with expectations, diversified layout continues to advance" and other reports, maintain the "Buy" rating of Tofflon
.
From the major reports, the main reasons for maintaining the “Buy” rating of Tofflon include: from the demand side, the huge increase in biopharmaceutical equipment will promote the accelerated expansion of the pharmaceutical equipment industry; from the supply side , The pharmaceutical equipment industry is accelerating the upgrade, bringing more room for increment to the industry; from the perspective of internationalization, domestic pharmaceutical equipment companies are accelerating their internationalization layout and opening up the growth ceiling
.
In addition, on the company side, in the era of biopharmaceuticals, Tofflon's product line has a complete layout.
As a domestic leader, it is gaining momentum, and its high performance growth is sustainable
.
On October 25, Southwest Securities released the report "Downstream Demand Maintains High Prosperity, and Third Quarter Results Exceeds Expectations", maintaining the "Buy" rating of Chutian Technology
.
The reasons for the rating mainly include: Q3 overall performance exceeded expectations; the downstream pharmaceutical industry is booming and the company's profitability continues to improve; Chutian Siyoute and Chutian Microsphere have been established successively to deploy high-barrier biopharmaceutical consumables business
.
The industry believes that the pharmaceutical equipment industry is ushering in a new round of growth
.
Under the current rapid development of the biopharmaceutical industry and the trend of smart manufacturing, the pharmaceutical industry will accelerate its transformation and upgrading, driving the growth of demand in the mid-to-high-end market
.
Data show that the size of China's pharmaceutical equipment market in 2020 is about 35.
9 billion yuan.
It is speculated that by 2021, the size of China's pharmaceutical equipment market can approach 40 billion yuan
.